MSP-1014

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.^{[3][4][5][1][2]}

MSP-1014

Clinical data
Other names	MSP1014; MSP-1014.OX
Routes of administration	Oral[1][2]
Drug class	Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor.^[3][5][2][6]

The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical.^[3][4][5] As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders.^[3][4][5] The chemical structure of MSP-1014 does not yet seem to have been disclosed.^[3][4] However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.^[7]

See also

• List of investigational hallucinogens and entactogens
• CT-4201
• EB-002
• RE-109
• RE-104